CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

Read more

Our innovative solutions

CarThera’s medical devices allow for the treatment of brain tumors in outpatient procedures as well as for improvement in the bioavailability of chemotherapeutics

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

Read more

SonoCloud®

High Intensity Contact Ultrasound interstitial medical device

An implant that increases the intracerebral penetration of oncology drugs (+400%) by transiently opening the blood-brain barrier (BBB) without increasing dose or subsequent toxicity. The minimally invasive and easy to use SonoCloud® device is also applicable to the treatment of neurodegenerative diseases (e.g. Alzheimer’s).

Read more

 

SonoProbe®

High Intensity Contact Ultrasound interstitial medical device

img2

The only medical device capable of performing biopsy, treatment, and resection of brain tumors in a single, image-guided outpatient procedure, even for complex tumor geometries

The SonoProbe can also be used for the treatment of tumors located in other organs such as the liver or lung

Read more

Home Page
  • unnamed-2
    unnamed-3

     
  • News CarThera

    06.01.2021
    December 2020: CarThera starts phase I/II trial in collaboration with Northwestern University

    CarThera announces the launch of a new phase I/II clinical trial (NCT04528680) in collaboration with Northwestern University in Chicago. The trial will recruit up to 39 patients with recurrent glioblastoma (GBM) to test the SonoCloud-9 device in combination with Abraxane® – an albumin-bound formulation of paclitaxel. The first patient in this trial has been treated and further patient recruitment is now on-going. The goal of the trial is to determine the safe dose of Abraxane to be used in combination with the SonoCloud-9 device in recurrent GBM patients (Phase I); then expand with the established safe dose in order to evaluate preliminary efficacy (Phase II).

    06.01.2021
    September 2020: CarThera to receive €2M grant and €10.5M equity from the European Innovation Council

    CarThera announces that it has been selected by the EIC Accelerator Pilot to receive a €2 million ($2.3M) grant and €10.5M ($12M) in equity for the development of its DOMEUS project for the treatment of glioblastoma (GBM) patients. The company will also receive business coaching and mentoring to accompany its growth. With the DOMEUS project, CarThera will be able to scale-up its processes and organizational structure to bring its technology to an increasing number of patients around the world.

    09.06.2020
    June 2020: CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

    CarThera announces that the first patient has been enrolled and treated in a clinical trial evaluating the safety of using its SonoCloud® technology in combination with checkpoint inhibitors for the treatment of brain metastases from melanoma (NCT04021420). In this trial, anti-PD1 alone or in combination with anti-CTLA4 are administered in patients before SonoCloud-mediated Blood Brain Barrier opening (BBB). BBB opening can help boost the brain’s immunity and increase brain penetration of newly approved systemically delivered immunotherapies, such as checkpoint inhibitors. This could translate into controlling brain disease with the same magnitude as peripheral diseases, improving clinical outcomes for many patients worldwide.